Why the study?
What is the contribution of arrhythmia to sudden death in dilated cardiomyopathy and what are the current treatment options?
Population
Patients with dilated cardiomyopathy (DCM)
Design
Review
Authors
Loading...
Reinforces arrhythmia as key sudden-death driver in DCM with ACEI mortality benefit; leaves open optimal roles of beta-blockers, amiodarone, and ICDs.
What is the contribution of arrhythmia to sudden death in dilated cardiomyopathy and what are the current treatment options?
This review highlights that sudden death in dilated cardiomyopathy is largely driven by ventricular arrhythmias, with ACE inhibitors being a mainstay of therapy to improve mortality.
Wu et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: